Oxford BioDynamics Plc (LON: OBD) has entered into a master service agreement for the development of predictive EpiSwitch™ biomarkers with a leading pharmaceutical company of the United States.
- The master service agreement allows the US pharmaceutical company access to OBD's unique EpiSwitch™ technology for use in the development of predictive biomarkers.
- Though the details of the agreement and financial terms were not disclosed, but it builds on OBD's proven ability to develop predictive biomarkers for response in immuno-oncology.
- On 20th December 2019, at the time of writing, GMT 08:03 AM, OBD shares were trading at GBX 105.00, up by 1.50 points or 1.45% against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.